 Justin Honce
Concepts (146)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Magnetic Resonance Imaging | 15 | 2023 | 3174 | 1.130 |
Why?
| | Multiple Sclerosis | 4 | 2021 | 384 | 0.870 |
Why?
| | Immunologic Factors | 2 | 2019 | 225 | 0.710 |
Why?
| | Glatiramer Acetate | 1 | 2019 | 20 | 0.690 |
Why?
| | Psychotherapy | 1 | 2020 | 177 | 0.640 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 1 | 2019 | 68 | 0.630 |
Why?
| | Rituximab | 1 | 2019 | 155 | 0.630 |
Why?
| | Epilepsy | 2 | 2017 | 290 | 0.530 |
Why?
| | Neuroimaging | 1 | 2016 | 256 | 0.480 |
Why?
| | Meningeal Neoplasms | 3 | 2021 | 90 | 0.390 |
Why?
| | Natalizumab | 2 | 2021 | 46 | 0.360 |
Why?
| | Cochlear Implantation | 2 | 2023 | 81 | 0.350 |
Why?
| | Cochlear Implants | 2 | 2023 | 91 | 0.350 |
Why?
| | Meningioma | 2 | 2021 | 82 | 0.350 |
Why?
| | Brain Concussion | 1 | 2016 | 470 | 0.340 |
Why?
| | Central Nervous System | 2 | 2021 | 245 | 0.320 |
Why?
| | Pyrazoles | 3 | 2021 | 363 | 0.300 |
Why?
| | Pyrimidines | 2 | 2021 | 382 | 0.290 |
Why?
| | Brain | 4 | 2021 | 2490 | 0.290 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 3 | 2021 | 968 | 0.280 |
Why?
| | Pyridines | 2 | 2021 | 440 | 0.260 |
Why?
| | Central Nervous System Diseases | 1 | 2023 | 64 | 0.210 |
Why?
| | Parkinson Disease | 2 | 2017 | 334 | 0.210 |
Why?
| | Middle Aged | 14 | 2022 | 27617 | 0.210 |
Why?
| | Lung Neoplasms | 3 | 2021 | 2220 | 0.200 |
Why?
| | Proto-Oncogene Proteins c-ret | 1 | 2021 | 25 | 0.200 |
Why?
| | Intracranial Aneurysm | 1 | 2022 | 99 | 0.200 |
Why?
| | Atrophy | 1 | 2021 | 164 | 0.190 |
Why?
| | Hypnosis | 1 | 2020 | 9 | 0.190 |
Why?
| | Relaxation Therapy | 1 | 2020 | 14 | 0.190 |
Why?
| | Radiology, Interventional | 1 | 2020 | 28 | 0.180 |
Why?
| | Humans | 25 | 2023 | 118974 | 0.180 |
Why?
| | Radiology Department, Hospital | 1 | 2019 | 18 | 0.180 |
Why?
| | Skull Base Neoplasms | 1 | 2019 | 29 | 0.170 |
Why?
| | Maintenance Chemotherapy | 1 | 2019 | 23 | 0.170 |
Why?
| | Cerebral Arterial Diseases | 1 | 2019 | 43 | 0.170 |
Why?
| | Antineoplastic Agents | 2 | 2021 | 1974 | 0.170 |
Why?
| | Induction Chemotherapy | 1 | 2019 | 59 | 0.170 |
Why?
| | Lactams, Macrocyclic | 1 | 2018 | 47 | 0.170 |
Why?
| | Neurologic Examination | 1 | 2019 | 126 | 0.160 |
Why?
| | Blepharospasm | 1 | 2018 | 7 | 0.160 |
Why?
| | Torticollis | 1 | 2018 | 12 | 0.160 |
Why?
| | Demyelinating Diseases | 1 | 2019 | 79 | 0.160 |
Why?
| | Adult | 11 | 2022 | 31512 | 0.160 |
Why?
| | Basal Ganglia | 1 | 2018 | 44 | 0.160 |
Why?
| | Posterior Leukoencephalopathy Syndrome | 1 | 2018 | 9 | 0.160 |
Why?
| | Fingolimod Hydrochloride | 1 | 2018 | 32 | 0.160 |
Why?
| | Organophosphorus Compounds | 1 | 2018 | 76 | 0.160 |
Why?
| | Brain Neoplasms | 2 | 2016 | 1022 | 0.150 |
Why?
| | Sinus Thrombosis, Intracranial | 1 | 2017 | 22 | 0.150 |
Why?
| | Epilepsy, Temporal Lobe | 1 | 2017 | 20 | 0.150 |
Why?
| | Disability Evaluation | 1 | 2019 | 280 | 0.150 |
Why?
| | Academic Medical Centers | 1 | 2019 | 422 | 0.150 |
Why?
| | Spin Labels | 1 | 2016 | 50 | 0.140 |
Why?
| | Cerebellum | 1 | 2018 | 203 | 0.140 |
Why?
| | Surgery, Computer-Assisted | 1 | 2017 | 69 | 0.140 |
Why?
| | Laser Therapy | 1 | 2017 | 104 | 0.140 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2016 | 105 | 0.130 |
Why?
| | Medical Marijuana | 1 | 2017 | 102 | 0.130 |
Why?
| | Brain Ischemia | 1 | 2019 | 310 | 0.130 |
Why?
| | Gray Matter | 1 | 2015 | 66 | 0.130 |
Why?
| | Gene Rearrangement | 1 | 2015 | 141 | 0.130 |
Why?
| | Immunosuppressive Agents | 1 | 2019 | 681 | 0.130 |
Why?
| | Cerebrovascular Circulation | 1 | 2016 | 204 | 0.120 |
Why?
| | Neurosurgical Procedures | 1 | 2016 | 164 | 0.120 |
Why?
| | Double-Blind Method | 1 | 2019 | 1687 | 0.120 |
Why?
| | Mitochondrial Diseases | 1 | 2015 | 79 | 0.120 |
Why?
| | Anxiety | 1 | 2020 | 845 | 0.120 |
Why?
| | Nucleus Accumbens | 1 | 2015 | 131 | 0.120 |
Why?
| | Health Services Accessibility | 1 | 2019 | 781 | 0.110 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2015 | 229 | 0.110 |
Why?
| | Endovascular Procedures | 1 | 2017 | 276 | 0.110 |
Why?
| | Glioma | 1 | 2016 | 306 | 0.110 |
Why?
| | Male | 13 | 2023 | 57801 | 0.100 |
Why?
| | Contrast Media | 3 | 2021 | 373 | 0.100 |
Why?
| | Quality Improvement | 1 | 2019 | 963 | 0.100 |
Why?
| | Female | 13 | 2022 | 61565 | 0.100 |
Why?
| | Brain Injuries | 1 | 2016 | 484 | 0.100 |
Why?
| | Cannabis | 1 | 2017 | 382 | 0.100 |
Why?
| | Young Adult | 3 | 2021 | 10793 | 0.100 |
Why?
| | Artifacts | 2 | 2023 | 125 | 0.090 |
Why?
| | Diagnosis, Differential | 1 | 2015 | 1384 | 0.090 |
Why?
| | Quality of Life | 1 | 2021 | 2366 | 0.090 |
Why?
| | Hippocampus | 1 | 2015 | 735 | 0.090 |
Why?
| | Stroke | 1 | 2019 | 1047 | 0.090 |
Why?
| | Retrospective Studies | 6 | 2022 | 12978 | 0.080 |
Why?
| | Aged | 7 | 2022 | 19657 | 0.080 |
Why?
| | Sensitivity and Specificity | 2 | 2022 | 1795 | 0.070 |
Why?
| | Substance-Related Disorders | 1 | 2015 | 971 | 0.070 |
Why?
| | Adolescent | 2 | 2021 | 18480 | 0.070 |
Why?
| | Monkeypox virus | 1 | 2023 | 12 | 0.060 |
Why?
| | Angiography, Digital Subtraction | 1 | 2022 | 46 | 0.050 |
Why?
| | Cerebral Angiography | 1 | 2022 | 116 | 0.050 |
Why?
| | Computed Tomography Angiography | 1 | 2022 | 81 | 0.050 |
Why?
| | Artificial Intelligence | 1 | 2022 | 140 | 0.050 |
Why?
| | Disease Progression | 2 | 2019 | 2490 | 0.050 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2023 | 508 | 0.050 |
Why?
| | Hospital Bed Capacity, 500 and over | 1 | 2019 | 3 | 0.050 |
Why?
| | Time Management | 1 | 2019 | 16 | 0.050 |
Why?
| | Treatment Outcome | 3 | 2018 | 9342 | 0.040 |
Why?
| | Magnets | 1 | 2019 | 15 | 0.040 |
Why?
| | Appointments and Schedules | 1 | 2019 | 78 | 0.040 |
Why?
| | Transportation of Patients | 1 | 2019 | 49 | 0.040 |
Why?
| | Prognosis | 2 | 2019 | 3443 | 0.040 |
Why?
| | Efficiency, Organizational | 1 | 2019 | 126 | 0.040 |
Why?
| | Lactams | 1 | 2018 | 38 | 0.040 |
Why?
| | Drug Approval | 1 | 2018 | 77 | 0.040 |
Why?
| | Tomography Scanners, X-Ray Computed | 1 | 2018 | 18 | 0.040 |
Why?
| | Aminopyridines | 1 | 2018 | 85 | 0.040 |
Why?
| | Databases, Bibliographic | 1 | 2018 | 29 | 0.040 |
Why?
| | Diffusion Tensor Imaging | 1 | 2018 | 73 | 0.040 |
Why?
| | Gadolinium | 1 | 2018 | 79 | 0.040 |
Why?
| | Dura Mater | 1 | 2017 | 29 | 0.040 |
Why?
| | Lymphoma, B-Cell | 1 | 2018 | 85 | 0.040 |
Why?
| | Aged, 80 and over | 2 | 2019 | 6561 | 0.040 |
Why?
| | Neoplasm Metastasis | 1 | 2018 | 544 | 0.040 |
Why?
| | Mood Disorders | 1 | 2017 | 119 | 0.040 |
Why?
| | Memory Disorders | 1 | 2017 | 168 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2019 | 278 | 0.030 |
Why?
| | Radiosurgery | 1 | 2019 | 318 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2018 | 736 | 0.030 |
Why?
| | Inpatients | 1 | 2019 | 388 | 0.030 |
Why?
| | Recurrence | 1 | 2018 | 975 | 0.030 |
Why?
| | Memory | 1 | 2017 | 230 | 0.030 |
Why?
| | Fatigue | 1 | 2017 | 297 | 0.030 |
Why?
| | Affect | 1 | 2017 | 240 | 0.030 |
Why?
| | Limbic System | 1 | 2015 | 42 | 0.030 |
Why?
| | Disabled Persons | 1 | 2017 | 147 | 0.030 |
Why?
| | Length of Stay | 1 | 2019 | 1032 | 0.030 |
Why?
| | Tremor | 1 | 2015 | 46 | 0.030 |
Why?
| | Survival Analysis | 1 | 2018 | 1267 | 0.030 |
Why?
| | Gait Disorders, Neurologic | 1 | 2015 | 40 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2017 | 1166 | 0.030 |
Why?
| | Marijuana Smoking | 1 | 2017 | 220 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 1868 | 0.030 |
Why?
| | Anticoagulants | 1 | 2017 | 559 | 0.030 |
Why?
| | Internet | 1 | 2017 | 633 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 1 | 2022 | 2436 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2019 | 2874 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2674 | 0.020 |
Why?
| | Sex Factors | 1 | 2015 | 1781 | 0.020 |
Why?
| | Colorado | 1 | 2019 | 4196 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2017 | 4596 | 0.020 |
Why?
| | Time Factors | 1 | 2018 | 6412 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2017 | 4708 | 0.020 |
Why?
| | Obesity | 1 | 2017 | 2746 | 0.020 |
Why?
|
|
Honce's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|